Arthur G. Fitzmaurice

TL;DR: Parkinsons disease (PD) is a progressive motor disorder characterized by death of dopaminergic neurons in the region of the brain called the substantia nigra pars compacta although other areas of the central and peripheral nervous system are involved.

TL;DR: It is proposed that benomyl, via its bioactivated thiocarbamate sulfoxide metabolite, inhibits aldehyde dehydrogenase (ALDH), leading to accumulation of the reactive dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), preferential degeneration of dopamine neurons, and development of PD.

TL;DR: The data suggest that CLR01 is a promising therapeutic agent for the treatment of Parkinson’s disease and other synucleinopathies.

TL;DR: ALDH inhibition appears to be an important mechanism through which environmental toxicants contribute to PD pathogenesis, especially in genetically vulnerable individuals, suggesting several potential interventions to reduce PD occurrence or slow or reverse its progression.

TL;DR: It is demonstrated that ziram causes selective dopaminergic cell damage in vitro by inhibiting an important degradative pathway implicated in the etiology of PD.